Literature DB >> 8725400

Imidazoline receptors and their endogenous ligands.

S Regunathan1, D J Reis.   

Abstract

Imidazoline (I) receptors constitute a family of nonadrenergic high-affinity binding sites for clonidine, idazoxan, and allied drugs. One major subclass, the I1 receptors, whose subcellular distribution and signal transduction mechanisms are uncertain, partly mediates the central hypotensive actions of clonidine-like drugs. The I2 receptors, another subclass, are mitochondrial, not G protein coupled, and have diversified functions. Several endogenous ligands for I receptors, collectively termed clonidine-displacing substances (CDSs), have been detected in tissues and serum, but the structure of only one, agmatine (decarboxylated arginine), is known. Agmatine, widely distributed and bioactive, binds, like clonidine, to alpha 2-adrenergic and I receptors of all subclasses. The presence of agmatine and its biosynthetic enzyme in synaptosomes and specific neuronal pathways as well as serum suggests that it may be a novel neurotransmitter/hormone. Another CDS that binds to I receptors and to antibodies to imidazoline drugs has been detected, but its structure is unknown.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8725400     DOI: 10.1146/annurev.pa.36.040196.002455

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  39 in total

Review 1.  Drugs acting on imidazoline receptors: a review of their pharmacology, their use in blood pressure control and their potential interest in cardioprotection.

Authors:  P Bousquet; J Feldman
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

Review 2.  Drugs for the perioperative control of hypertension: current issues and future directions.

Authors:  Robert Feneck
Journal:  Drugs       Date:  2007       Impact factor: 9.546

3.  Agmatine, an endogenous modulator of noradrenergic neurotransmission in the rat tail artery.

Authors:  C González; S Regunathan; D J Reis; C Estrada
Journal:  Br J Pharmacol       Date:  1996-10       Impact factor: 8.739

4.  Protection by imidazol(ine) drugs and agmatine of glutamate-induced neurotoxicity in cultured cerebellar granule cells through blockade of NMDA receptor.

Authors:  G Olmos; N DeGregorio-Rocasolano; M Paz Regalado; T Gasull; M Assumpció Boronat; R Trullas; A Villarroel; J Lerma; J A García-Sevilla
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

Review 5.  The I1-imidazoline receptor: from binding site to therapeutic target in cardiovascular disease.

Authors:  P Ernsberger; J E Friedman; R J Koletsky
Journal:  J Hypertens Suppl       Date:  1997-01

6.  Behavioral and Cognitive Improvement Induced by Novel Imidazoline I2 Receptor Ligands in Female SAMP8 Mice.

Authors:  Christian Griñán-Ferré; Foteini Vasilopoulou; Sònia Abás; Sergio Rodríguez-Arévalo; Andrea Bagán; Francesc X Sureda; Belén Pérez; Luis F Callado; Jesús A García-Sevilla; M Julia García-Fuster; Carmen Escolano; Mercè Pallàs
Journal:  Neurotherapeutics       Date:  2019-04       Impact factor: 7.620

7.  Anti-hyperalgesic effects of imidazoline I2 receptor ligands in a rat model of inflammatory pain: interactions with oxycodone.

Authors:  David A Thorn; Justin N Siemian; Yanan Zhang; Jun-Xu Li
Journal:  Psychopharmacology (Berl)       Date:  2015-06-04       Impact factor: 4.530

8.  Imidazoleacetic acid-ribotide in vestibulo-sympathetic pathway neurons.

Authors:  Gay R Holstein; Victor L Friedrich; Giorgio P Martinelli
Journal:  Exp Brain Res       Date:  2016-07-13       Impact factor: 1.972

9.  Interactions between imidazoline I2 receptor ligands and acetaminophen in adult male rats: antinociception and schedule-controlled responding.

Authors:  Justin N Siemian; Jiuzhou Li; Yanan Zhang; Jun-Xu Li
Journal:  Psychopharmacology (Berl)       Date:  2015-11-28       Impact factor: 4.530

10.  Antineoplastic activity of idazoxan hydrochloride.

Authors:  G F Eilon; L Weisenthal; M Stupecky; G Landucci; L M Slater
Journal:  Cancer Chemother Pharmacol       Date:  2009-03-24       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.